Deutsche Bank’s Eiger BioPharmaceuticals, Inc. EIGR Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2023
Q2 | – | Sell |
-824
| Closed | -$22.2K | – | 4002 |
|
|
2023
Q1 | $22.2K | Buy |
824
+221
| +37% | +$10.3K | ﹤0.01% | 3704 |
|
|
2022
Q4 | $21.3K | Buy |
603
+10
| +2% | +$1.2K | ﹤0.01% | 3761 |
|
|
2022
Q3 | $134K | Sell |
593
-92
| -13% | -$22.6K | ﹤0.01% | 3174 |
|
|
2022
Q2 | $129K | Buy |
685
+106
| +18% | +$21.4K | ﹤0.01% | 3392 |
|
|
2022
Q1 | $144K | Sell |
579
-69
| -11% | -$10.9K | ﹤0.01% | 3431 |
|
|
2021
Q4 | $101K | Buy |
648
+34
| +6% | +$6.58K | ﹤0.01% | 3699 |
|
|
2021
Q3 | $123K | Sell |
614
-19
| -3% | -$4.52K | ﹤0.01% | 3812 |
|
|
2021
Q2 | $162K | Sell |
633
-74
| -10% | -$18.5K | ﹤0.01% | 3907 |
|
|
2021
Q1 | $187K | Sell |
707
-62
| -8% | -$19.5K | ﹤0.01% | 3666 |
|
|
2020
Q4 | $284K | Buy |
769
+255
| +50% | +$73.1K | ﹤0.01% | 3259 |
|
|
2020
Q3 | $125K | Buy |
514
+127
| +33% | +$39.5K | ﹤0.01% | 3443 |
|
|
2020
Q2 | $111K | Sell |
387
-1,369
| -78% | -$404K | ﹤0.01% | 3391 |
|
|
2020
Q1 | $358K | Buy |
1,756
+1,324
| +306% | +$422K | ﹤0.01% | 2650 |
|
|
2019
Q4 | $192K | Buy |
432
+210
| +95% | +$74.5K | ﹤0.01% | 3251 |
|
|
2019
Q3 | $67K | Sell |
222
-706
| -76% | -$229K | ﹤0.01% | 3775 |
|
|
2019
Q2 | $293K | Sell |
928
-56
| -6% | -$19.4K | ﹤0.01% | 3617 |
|
|
2019
Q1 | $412K | Sell |
984
-473
| -32% | -$190K | ﹤0.01% | 3568 |
|
|
2018
Q4 | $443K | Sell |
1,457
-362
| -20% | -$117K | ﹤0.01% | 3427 |
|
|
2018
Q3 | $655K | Sell |
1,819
-96
| -5% | -$32.8K | ﹤0.01% | 3604 |
|
|
2018
Q2 | $701K | Buy |
+1,915
| New | +$682K | ﹤0.01% | 3652 |
|
|
2018
Q1 | – | Sell |
-388
| Closed | -$115K | – | 5653 |
|
|
2017
Q4 | $162K | Sell |
388
-2,686
| -87% | -$960K | ﹤0.01% | 4110 |
|
|
2017
Q3 | $1.01M | Buy |
3,074
+1,407
| +84% | +$383K | ﹤0.01% | 3001 |
|
|
2017
Q2 | $395K | Buy |
1,667
+329
| +25% | +$74.8K | ﹤0.01% | 3581 |
|
|
2017
Q1 | $458K | Sell |
1,338
-25
| -2% | -$8.61K | ﹤0.01% | 3126 |
|
|
2016
Q4 | $474K | Buy |
1,363
+441
| +48% | +$162K | ﹤0.01% | 3203 |
|
|
2016
Q3 | $369K | Sell |
922
-135
| -13% | -$68.9K | ﹤0.01% | 3348 |
|
|
2016
Q2 | $627K | Buy |
1,057
+514
| +95% | +$312K | ﹤0.01% | 3154 |
|
|
2016
Q1 | $273K | Sell |
543
-56
| -9% | -$27.9K | ﹤0.01% | 3511 |
|
|
2015
Q4 | $395K | Buy |
599
+585
| +4,179% | +$331K | ﹤0.01% | 3383 |
|
|
2015
Q3 | $6K | Buy |
14
+2
| +17% | +$1.06K | ﹤0.01% | 5027 |
|
|
2015
Q2 | $6K | Sell |
12
-261
| -96% | -$722K | ﹤0.01% | 5128 |
|
|
2015
Q1 | $2.33M | Buy |
273
+230
| +535% | +$2.01M | ﹤0.01% | 2328 |
|
|
2014
Q4 | $375K | Buy |
43
+23
| +115% | +$133K | ﹤0.01% | 3871 |
|
|
2014
Q3 | $94K | Sell |
20
-1
| -5% | -$5.28K | ﹤0.01% | 4534 |
|
|
2014
Q2 | $148K | Buy |
21
+17
| +425% | +$85.1K | ﹤0.01% | 4326 |
|
|
2014
Q1 | $18K | Buy |
+4
| New | +$18.9K | ﹤0.01% | 4878 |
|
Other funds holding EIGR
6CM
SAM
UOC
RC
GCP
Deutsche Bank's EIGR Position: Q2 2023 in Review
Deutsche Bank sold out of Eiger BioPharmaceuticals, Inc. (EIGR) in Q2 2023, closing a stake of 824 shares — an estimated $22.2K sold.
Deutsche Bank first reported a position in EIGR in Q1 2014 and held it in 36 quarters. The position peaked at $2.33M in Q1 2015. 66 funds tracked by Wall St. Rank hold EIGR as of Q2 2023.
- Deutsche Bank reported no remaining Eiger BioPharmaceuticals, Inc. position as of Q2 2023 after selling out during the quarter.
- Deutsche Bank sold 824 Eiger BioPharmaceuticals, Inc. shares in Q2 2023, an estimated $22.2K.
- Deutsche Bank first reported a position in Eiger BioPharmaceuticals, Inc. in Q1 2014 and held it in 36 quarters.
- Deutsche Bank's Eiger BioPharmaceuticals, Inc. position peaked at $2.33M in Q1 2015.
- 66 funds tracked by Wall St. Rank held Eiger BioPharmaceuticals, Inc. as of Q2 2023.
Based on Deutsche Bank's 13F filing for Q2 2023, filed 14 Aug 2023.